Drug Profile
Research programme: matrix metalloproteinase 13 inhibitors - Wyeth
Latest Information Update: 31 Mar 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer; Wyeth
- Class
- Mechanism of Action Matrix metalloproteinase 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 31 Aug 2009 This programme is still in active development with Wyeth in the US
- 21 Sep 2005 Preclinical trials in Osteoarthritis in USA (PO)